Antidepressant and antipsychotic drugs

Sleep Medicine Clinics

Volumn 5, Issue 4, 2010, Pages 571-589

  Krystal, Andrew D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antidepressant drugs; Antipsychotic drugs; Pharmacologic effects; Sleep wake effects

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HALOPERIDOL; ISOCARBOXAZID; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENELZINE; QUETIAPINE; RISPERIDONE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIOTIXENE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; CHOLINERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; DELTA RHYTHM; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; GENETIC POLYMORPHISM; HUMAN; INSOMNIA; MAJOR DEPRESSION; METABOLISM; NONREM SLEEP; PERIODIC LIMB MOVEMENT DISORDER; PRIORITY JOURNAL; REM SLEEP; RESTLESS LEGS SYNDROME; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP TIME; SLEEP WAKING CYCLE; SLOW BRAIN WAVE; SLOW WAVE SLEEP; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; WAKEFULNESS;

EID: 78649341896     PISSN: 1556407X     EISSN: 15564088     Source Type: Journal    
DOI: 10.1016/j.jsmc.2010.08.010     Document Type: Review

References (153)

1. C.B. Saper, T.E. Scammell, and J. Lu Hypothalmic regulation of sleep and circadian rhythms Nature 437 2005 1257 1263
2. A. Krystal A compendium of placebo-controlled trials of the risks/benefits of pharmacologic treatments for insomnia: the empirical basis for U.S. clinical practice Sleep Med Rev 13 4 2009 265 274
3. S.M. Stahl Essential Psychopharmacology 2nd edition 2000 Cambridge University Press New York
4. A.G. Mayers, and D.A. Baldwin Antidepressants and their effect on sleep Hum Psychopharmacol 20 8 2005 533 559
5. E. Richelson Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance J Clin Psychiatry 64 Suppl 13 2003 5 12
6. R. Baldessarini Drug therapy of depression and anxiety disorders L.L. Brunton, J.S. Lazo, K.L. Parker, Goodman and Gilman's: the pharmacological basis of therapeutics 11th edition 2006 McGraw-Hill New York 429 460
7. K. Adam, and I. Oswald Effects of repeated ritanserin on middle-aged poor sleepers Psychopharmacology (Berl) 99 2 1989 219 221
8. H.P. Landolt, V. Meier, and H.J. Burgess Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra Neuropsychopharmacology 21 3 1999 455 466
9. S.R. Morairty, L. Hedley, and J. Flores Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats Sleep 31 1 2008 34 44
10. R. Rosenberg, D.J. Seiden, and S.G. Hull APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia Sleep 31 12 2008 1663 1671
11. J.S. Lin, Y. Dauvilliers, and I. Arnulf An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients Neurobiol Dis 30 2008 74 83
12. E. Richelson, and A. Nelson Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro J Pharmacol Exp Ther 230 1 1984 94 102
13. A.D. Krystal, H. Goforth, and T. Roth Effects of antipsychotic medications on sleep in schizophrenia Int Clin Psychopharmacol 23 2008 150 160
14. T. Roth, R. Rogowski, and S. Hull Efficacy and safety of doxepin 1, 3 and 6 mg in adults with primary insomnia Sleep 30 2007 1555 1561
15. Krystal AD, Durrence H, Scharf M, et al. Long-term efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep, in press.
16. C.W. Berridge Neural substrates of psychostimulant-induced arousal Neuropsychopharmacology 31 11 2006 2332 2340
17. I. Hilakivi, A. Leppavuori, and P.T. Putkonen Prazosin increases paradoxical sleep Eur J Pharmacol 65 1980 417 420
18. I. Hilakivi, and A. Leppavuori Effects of methoxamine, and alpha-1 adrenoceptor agonist, and prazosin, an alpha-1 antagonist, on the stages of the sleep-waking cycle in the cat Acta Physiol Scand 120 1984 363 372
19. R. Lydic, and H.A. Baghdoyan Acetylcholine modulates sleep and wakefulness: a synaptic perspective J.M. Monti, S.R. Pandi-Perumal, C.M. Sinton, Neurochemistry of sleep and wakefulness 2008 Cambridge University Press Cambridge (UK) 109 143
20. T. Kanai, and J.C. Szerb Mesencephalic reticular activating system and cortical acetylcholine output Nature 205 1965 80 82
21. L. Imeri, S. Bianchi, and P. Angeli Selective blockade of different brain stem muscarinic receptor subtypes: effects on the sleep-wake cycle Brain Res 636 1994 68 72
22. C.B. Nemeroff, and M.J. Owens Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis CNS Spectr 9 6 Suppl 4 2004 23 31
23. D.J. Nutt The neuropharmacology of serotonin and noradrenaline in depression Int Clin Psychopharmacol 17 Suppl 1 2002 S1 12
24. M.J. Owens, D.L. Knight, and C.B. Nemeroff Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine Biol Psychiatry 50 5 2001 345 350
25. B.E. Leonard Serotonin receptors and their function in sleep, anxiety disorders and depression Psychother Psychosom 65 1996 66 75
26. S.J. Wilson, J.E. Bailey, and A.S. Rich The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans Psychopharmacology 19 2005 609 613
27. A. Leppävuori The effects of an alpha-adrenergic agonist or antagonist on sleep during blockade of catecholamine synthesis in the cat Brain Res 193 1 1980 117 128
28. X.H. Hu, A.B. Scott, and E.M. Hunkeler Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate J Clin Psychiatry 65 2004 959 965
29. M. Fava, A.J. Rush, and M.E. Thase 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL Prim Care Companion J Clin Psychiatry 7 3 2005 106 113
30. A.L. Sharpley, D.J. Williamson, and M.E. Attenburrow The effects of paroxetine and nefazodone on sleep: a placebo controlled trial Psychopharmacology 126 1996 50 54
31. S.M. Stahl, J.F. Pradko, and B.R. Haight A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor Prim Care Companion J Clin Psychiatry 6 2004 159 166
32. N.B. Mehta The chemistry of bupropion J Clin Psychiatry 44 5 Pt 2 1983 56 59
33. A. Bolasco, S. Carradori, and R. Fioravanti Focusing on new monoamine oxidase inhibitors Expert Opin Ther Pat 20 7 2010 909 939
34. D.L. Murphy, T. Sunderland, and R.M. Cohen Monoamine oxidase-inhibiting antidepressants. A Clinical update Psychiatr Clin North Am 7 1984 546 562
35. F. Quitkin, A. Rifkin, and D.F. Klein Monoamine oxidase inhibitors. A review of antidepressant effectiveness Arch Gen Psychiatry 36 7 1979 749 760
36. R.E. Poland, J.T. McCracken, and P. Lutchmansingh Differential response of rapid eye movement sleep to cholinergic blockade by scopolamine in currently depressed, remitted, and normal control subjects Biol Psychiatry 41 9 1997 929 938
37. M. Maes, H. Westenberg, and E. Vandoolaeghe Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine J Clin Psychopharmacol 17 5 1997 358 364
38. R.M. Benca, W.H. Obermeyer, and R.A. Thisted Sleep and psychiatric disorders. A meta-analysis Arch Gen Psychiatry 49 1992 651 668
39. J.C. Gillin, R.J. Wyatt, and D. Fram The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline Psychopharmacology (Berl) 59 1978 267 272
40. D.J. Kupfer, D.G. Spiker, and P.A. Coble Sleep and treatment prediction in endogenous depression Am J Psychiatry 138 1981 429 434
41. M.E. Thase Depression and sleep: pathophysiology and treatment Dialogues Clin Neurosci 8 2006 217 226
42. A.D. Krystal, M.E. Thase, and V.L. Tucker Bupropion HCL and sleep in patients with depression Clin Psychol Rev 3 2007 123 128 Curr Psychiatry Rev
43. J. Poulin, A.M. Daoust, and G. Forest Sleep architecture and its clinical correlates in first episode and neuroleptic-naive patients with schizophrenia Schizophr Res 62 2003 147 153
44. J.C. Ware, and J.T. Pittard Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults J Clin Psychiatry 51 Suppl 1990 18 22
45. A. Winokur, M.J. Sateia, and J.B. Hayes Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study Biol Psychiatry 48 1 2000 75 78
46. S. Aslan, E. Isik, and B. Cosar The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers Sleep 25 6 2002 677 679
47. M. Schittecatte, F. Dumont, and R. Machowski Effects of mirtazapine on sleep polygraphic variables in major depression Neuropsychobiology 46 4 2002 197 201
48. J.K. Walsh Enhancement of slow wave sleep: implications for insomnia J Clin Sleep Med 5 Suppl 2 2009 S27 S32
49. R. Goder, M. Boigs, and S. Braun Impairment of visuospatial memory is associated with decreased slow wave sleep in schizophrenia J Psychiatr Res 38 2004 591 599
50. R. Hoque, and A.L. Chesson Jr. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis J Clin Sleep Med 6 1 2010 79 83
51. M. Hornyak, B. Feige, and D. Riemann Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment Sleep Med Rev 10 2006 169 177
52. J.W. Winkelman, and L. James Serotonergic antidepressants are associated with REM sleep without atonia Sleep 27 2004 317 321
53. C. Yang, D.P. White, and J.W. Winkelman Antidepressants and periodic leg movements of sleep Biol Psychiatry 58 2005 510 514
54. A.M. Hughes, P. Lynch, and J. Rhodes Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers Br J Clin Pharmacol 48 3 1999 323 330
55. J.C. Gillin, W. Duncan, and K.D. Pettigrew Successful separation of depressed, normal, and insomniac subjects by EEG sleep data Arch Gen Psychiatry 36 1979 85 90
56. D.J. Kupfer, R.F. Ulrich, and P.A. Coble Elextroencephalographic sleep of younger depressives. Comparison with normals Arch Gen Psychiatry 42 1985 806 810
57. M. Berger, P. Doerr, and R. Lund Neuroendocrinological and neurophysiological studies in major depressive disorders: are there biological markers of the endogenous subtype? Biol Psychiatry 17 1982 1217 1242
58. C.F. Reynolds 3rd, E. Frank, and P.R. Houck Which elderly patients with remitted depression remain well with continued interpersonal psychotherapy after discontinuation of antidepressant medication? Am J Psychiatry 154 1997 958 962
59. A.A. Nierenberg, and E.C. Wright Evolution of remission as the new standard in the treatment of depression J Clin Psychiatry 60 Suppl 22 1999 7 11
60. E. Richelson Synaptic effects of antidepressants J Clin Psychopharmacol 16 3 Suppl 2 1996 1S 9S
61. C.F. Saller, and A.I. Salama Seroquel: biochemical profile of a potential atypical antipsychotic Psychopharmacology 112 1993 285 292
62. R. Tandon Neuropharmacological basis of clozapine's unique profile Arch Gen Psychiatry 50 1993 158 159
63. T.F. Seeger, P.A. Seymour, and A.W. Schmidt Ziprasidone: a new antipsychotic with combined dopamine and serotonin receptor antagonist activity J Pharmacol Exp Ther 275 1995 101 113
64. C.M. Beasley Jr., G. Tollefson, and P. Tran Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial Neuropsychopharmacology 14 1996 111 123
65. F.P. Bymaster, D.O. Calligaro, and J.F. Falcone Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 1996 87 96
66. A. Schotte, P.F. Janssen, and W. Gommeren Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding Psychopharmacology 124 1996 57 73
67. Y. Sekine, T. Rikihisa, and H. Ogata Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions Eur J Clin Pharmacol 55 1999 583 587
68. A. Farah Atypicality of atypical antipsychotics Prim Care Companion J Clin Psychiatry 7 2005 268 274
69. A. Newman-Tancredi, M.B. Assie, and N. Leduc Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia Int J Neuropsychopharmacol 8 2005 341 356
70. D.B. Allison, J.L. Mentore, and M. Heo Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry 156 1999 1686 1696
71. A. Bagnall, J. Kleijnen, and M. Leitner Ziprasidone for schizophrenia and severe mental illness Cochrane Database Syst Rev 4 2000 CD001945
72. A. Sultana, J. Reilly, and M. Fenton Thioridazine for schizophrenia Cochrane Database Syst Rev 2 2000 CD001944
73. B. Thornley, J. Rathbone, and C.E. Adams Chlorpromazine versus placebo for schizophrenia Cochrane Database Syst Rev 2 2003 CD000284
74. M. Srisurapanont, B. Maneeton, and N. Maneeton Quetiapine for schizophrenia Cochrane Database Syst Rev 2 2004 CD000967
75. L. Duggan, M. Fenton, and J. Rathbone Olanzapine for schizophrenia Cochrane Database Syst Rev 2 2005 CD001359
76. H.G. El-Sayeh, and C. Morganti Aripiprazole for schizophrenia Cochrane Database Syst Rev 2 2006 CD004578
77. M.B. Jayaram, P. Hosalli, and S. Stroup Risperidone versus olanzapine for schizophrenia Cochrane Database Syst Rev 2 2006 CD005237
78. C.B. Joy, C.E. Adams, and S.M. Lawrie Haloperidol versus placebo for schizophrenia Cochrane Database Syst Rev 4 2006 CD003082.81
79. A. Forsman, and R. Ohman Studies on serum protein binding of haloperidol Curr Ther Res Clin Exp 21 1977 245 255
80. H. He, and J.S. Richardson A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors Int Clin Psychopharmacol 10 1995 19 30
81. L. Ereshefsky Pharmacokinetics and drug interactions: update for new antipsychotics J Clin Psychiatry 57 Suppl 11 1996 12 15
82. D. Hinze-Selch, J. Mullington, and A. Orth Effects of clozapine on sleep: a longitudinal study Biol Psychiatry 42 1997 260 266
83. C. Prakash, A. Kamel, and J. Gummerus Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans Drug Metab Dispos 25 1997 863 872
84. S. Maixner, R. Tandon, and A. Eiser Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension Am J Psychiatry 155 1998 1600 1602
85. R.J. Salin-Pascual, M. Herrera-Estrella, and L. Galicia-Polo Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency Biol Psychiatry 46 1 1999 141 143
86. R.J. Salin-Pascual, M. Herrera-Estrella, and L. Galicia-Polo Low delta sleep predicted a good clinical response to olanzapine administration in schizophrenic patients Rev Invest Clin 56 2004 345 350
87. J.H. Lee, J.I. Woo, and H.Y. Meltzer Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia Psychiatry Res 103 2001 157 166
88. H. Yamashita, S. Morinobu, and S. Yamawaki Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol Psychiatry Res 109 2002 137 142
89. A.L. Sharpley, Z. Bhagwagar, and S. Hafizi Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients J Clin Psychiatry 64 2003 192 196
90. S. Cohrs, A. Rodenbeck, and Z. Guan Sleep-promoting properties of quetiapine in healthy subjects Psychopharmacology 174 2004 421 429
91. S. Cohrs, A. Meier, and A.C. Neumann Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects J Clin Psychiatry 66 2005 989 996
92. W. Tassaneeyakul, K. Kittiwattanagul, and S. Vannaprasaht Steady-state bioequivalence study of clozapine tablet in schizophrenic patients J Pharm Pharm Sci 8 2005 47 53
93. J.S. Markowitz, C.L. DeVane, and R.J. Malcolm Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers J Clin Pharmacol 46 2006 164 171
94. B.H. Flores, and A.F. Schatzberg Mitazapine A. Schatzberg, C. Nemeroff, The American psychiatric publishing textbook of psychopharmacology 2004 American Psychiatric Publishing, Inc Washington, DC 341 347
95. R.J. Baldessarini Drugs and the treatment of anxiety disorders: depression and anxiety disorders J.G. Hardman, L.E. Limbird, Goldman and Gilman's: the pharmacologic basis of therapeutics 2001 McGraw-Hill New York 447 483
96. M.V. Rudorfer, and W.Z. Potter Metabolism of tricyclic antidepressants Cell Mol Neurobiol 19 3 1999 373 409
97. M.V. Rudorfer, and W.Z. Potter Pharmacokinetics of antidepressants H.Y. Meltzer, Psychopharmacology: the third generation of progress 1987 Raven Press New York 1353 1363
98. V. Ziegler, J.T. Biggs, and A.B. Ardekani Contribution to the pharmacokinetics f amitriptyline J Clin Pharmacol 18 10 1978 462 467
99. J.E. Shipley, D.J. Kupfer, and S.J. Griffin Comparison of effects of desipramine and amitriptyline on EEG sleep of depressed patients Psychopharmacology 85 1985 14 22
100. D.L. Dunleavy, V. Brezinova, and I. Oswald Changes during weeks in effects of tricyclic drugs on the human sleep brain Br J Psychiatry 120 1972 663 672
101. T. Roth, F. Zorick, and R. Wittig The effects of doxepin HCl on sleep and depression J Clin Psychiatry 43 1982 366 368
102. P. Feuillade, D. Pringuey, and J.L. Belugou Trimipramine: acute and lasting effects on sleep in healthy and major depressive subjects J Affect Disord 24 1992 135 145
103. J.C. Ware, F.W. Brown, and P.J. Moorad Effects on sleep: a double-blind study comparing trimipramine to imipramine in depressed insomniac patients Sleep 12 1989 537 549
104. D. Riemann, U. Voderholzer, and S. Cohrs Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study Pharmacopsychiatry 35 5 2002 165 174
105. F. Hohagen, R.F. Montero, and E. Weiss Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci 244 2 1994 65 72
106. A. Rodenbeck, S. Cohrs, and W. Jordan The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia Psychopharmacology (Berl) 170 2003 423 428
107. G. Hajak, A. Rodenbeck, and L. Adler Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia Pharmacopsychiatry 29 5 1996 187 192
108. G. Hajak, A. Rodenbeck., and U. Voderholzer Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study J Clin Psychopharmacol 62 6 2001 453 463
109. M. Scharf, R. Rogowski, and S. Hull Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized double-blind, placebo-controlled crossover study J Clin Psychiatry 69 10 2008 1557 1564
110. D.J. Buysse, C.F. Reynolds, and C.C. Hoch Longitudinal effects of nortriptyline on EEG sleep and the likelihood of recurrence in elderly depressed patients Neuropsychopharmacology 14 4 1996 243 252
111. E. Hartmann, and J. Cravens The effects of long term administration of psychotropic drugs on human sleep: III. The effects of amitriptyline Psychopharmacology 33 1973 185 202
112. R.N. Golden, K. Dawkins, and L. Nicholas Trazadone and nefazodone A. Schatzberg, C. Nemeroff, The American psychiatric textbook of psychopharmacology 2004 American Psychiatric Textbook, Inc Washington, DC 315 325
113. S. Caccia, M. Ballabio, and R. Fanelli Determination of plasma and brain concentrations of trazodone and its metabolite, 1-m-chlorophenylpiperazine, by gas-liquid chromatography J Chromatogr 5 210 1981 311 318
114. D.J. Greenblatt, H. Friedman, and E.S. Burstein Trazodone kinetics: effects of age, gender and obesity Clin Pharmacol Ther 42 1987 193 200
115. M. Warner, C.A. Peabody, and H.A. Whiteford Trazodone and priapism J Clin Psychiatry 48 6 1987 244 245
116. I. Montgomery, I. Oswald, and K. Morgan Trazodone enhances sleep in subjective quality but not in objective duration Br J Clin Pharmacol 16 1983 139 144
117. G. Saletu-Zyhlarz, M. Abu-Bakr, and P. Anderer Insomnia in depression: differences in objective and subjective sleep awakening quality to normal controls and accute effects of trazadone Prog Neuropsychopharmacol Biol Psychiatry 26 2002 249 260
118. M.B. Scharf, and B.A. Sachais Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients J Clin Psychiatry 51 1990 13 17
119. J. Mouret, P. Lemoine, and M.P. Minuit Effects of trazodone on the sleep of depressed subjects - a polygraphic study Psychopharmacology 95 1988 37 43
120. A.A. Nierenberg, L.A. Adler, and E. Peselow Trazodone for antidepressant-associated insomnia Am J Psychiatry 151 1994 1069 1072
121. H. Kaynak, D. Kaynak, and E. Gozukirmizi The effects of trazodone on sleep in patients treated with stimulant antidepressants Sleep Med 5 1 2004 15 20
122. J.K. Walsh, M. Erman, and C.W. Erwin Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia Hum Psychopharmacol 13 1998 191 198
123. O. Le Bon, J.R. Murphy, and L. Staner Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations J Clin Psychopharmacol 23 4 2003 377 383
124. L. Parrino, M.C. Spaggiari, and M. Boselli Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia Psychopharmacology 116 1994 389 395
125. T. DeBoer The pharmacologic profile of mirtazapine J Clin Psychopharmacol 57 Suppl 4 1996 19 25
126. J. Fawcett, and R.L. Barkin Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression J Affect Disord 51 3 1998 267 285
127. A. Winokur, N.A. DeMartinis 3rd, and D.P. McNally Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia J Clin Psychiatry 64 10 2003 1224 1229
128. M. Sørensen, J. Jørgensen, and J. Viby-Mogensen A double-blind group comparative study using the new anti-depressant Org 3770, placebo and diazepam in patients with expected insomnia and anxiety before elective gynaecological surgery Acta Psychiatr Scand 71 4 1985 331 346
129. G.S. Ruigt, B. Kemp, and C.M. Groenhout Effect of the antidepressant Org 3770 on human sleep Eur J Clin Pharmacol 38 1990 551 554
130. C.F. Reynolds 3rd, D.J. Buysse, and M.D. Miller Paroxetine treatment of primary insomnia in older adults Am J Geriatr Psychiatry 14 9 2006 803 807
131. S. Chalon, A. Pereira, and E. Lainey Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects Psychopharmacology (Berl) 177 4 2005 357 365
132. R. Luthringer, M. Toussaint, and N. Schaltenbrand A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression Psychopharmacol Bull 32 4 1996 637 646
133. E.A. Nofzinger, C.F. Reynolds, and M.E. Thase REM sleep enhancement by bupropion in depressed men Am J Psychiatry 152 1995 274 276
134. E.A. Nofzinger, M.A. Fasiczka, and S. Berman Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder J Clin Psychiatry 61 2000 858 862
135. G.E. Ott, U. Rai, and I. Nuccio Effect of bupropion SR on REM sleep: relationship to antidepressant response Psychopharmacology 165 2002 29 36
136. G.E. Ott, U. Rao, and K.M. Lin Effect of treatment with bupropion on EEG sleep: relationship to antidepressant response Int J Neuropsychopharmacol 7 2001 275 281
137. L. Evans, S. Golshan, and J. Kelsoe Effects of rapid tryptophan depletion on sleep electroencephalogram and mood in subjects with partially remitted depression on bupropion Neuropsychopharmacology 27 2002 1016 1026
138. S. Miyamoto, G.E. Duncan, and C.E. Marx Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs Mol Psychiatry 10 2005 79 104
139. Collaborative Working Group on Clinical Trial Evaluations Adverse effects of the atypical antipsychotics paper J Clin Psychiatry 59 Suppl 12 1988 17 22
140. M.L. Clark, W.K. Huber, and D. Hill Pimozide in chronic schizophrenic outpatients Dis Nerv Syst 36 1975 137 141
141. A. Sultana, and T. McMonagle Pimozide for schizophrenia or related psychoses Cochrane Database Syst Rev 3 2000 CD001949
142. 11C]raclopride Psychopharmacology 107 1992 23 29
143. T.C. Wetter, J. Brunner, and T. Bronisch Restless legs syndrome probably induced by risperidone treatment Pharmacopsychiatry 35 2002 109 111
144. T. Kraus, A. Schuld, and T. Pollmacher Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine J Clin Psychopharmacol 19 1999 478 479
145. J.D. Urban, G.A. Vargas, and M. von Zastrow Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways Neuropsychopharmacology 32 2007 67 77
146. S. Gentile Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis Drug Saf 29 2006 303 319
147. A.L. Sharpley, C.M. Vassallo, and P.J. Cowen Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo Biol Psychiatry 47 5 2000 468 470
148. N. Lindberg, M. Virkkunen, and P. Tani Effect of a single-dose of olanzapine on sleep in healthy females and males Int Clin Psychopharmacol 17 4 2002 177 184
149. A.L. Sharpley, C.M. Vassallo, and E.C. Pooley Allelic variation in the 5-HT2C receptor (HT2RC) and the increase in slow wave sleep produced by olanzapine Psychopathology 153 2001 271 272
150. S. Gimenez, S. Clos, and S. Romero Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers Psychopharmacology 190 4 2007 507 516
151. A.L. Sharpley, M.E. Attenburrow, and S. Hafizi Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients J Clin Psychiatry 66 4 2005 450 454
152. R.A. Moreno, M.M. Hanna, and S.M. Tavares A double-blind comparison of the effect of the antipsychotics haloperidol and olanzapine on sleep in mania Braz J Med Biol Res 40 3 2007 357 366
153. M.H. Wiegand, F. Landry, and T. Bruckner Quetiapine in primary insomnia: a pilot study Psychopharmacology 196 2 2008 337 338